c-erbB-2 Positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease

European Journal of Cancer

Volumn 37, Issue 3, 2001, Pages 347-354

  Jukkola, A ^a   Bloigu, R ^a   Soini, Y ^a   Savolainen, E R ^a   Holli, K ^b   Blanco, G ^a  

^a UNIVERSITY OF OULU   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Breast cancer; c erbB 2; Predictive factor; Prognosis

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PARAFFIN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE C ERB; ONCOGENE C ERBB 2; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SOUTHERN BLOTTING; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, SOUTHERN; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTOR, ERBB-2; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0035125564     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00395-6     Document Type: Article

References (29)

1. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
2. ERBB2 amplification in breast cancer with high rate of proliferation
3. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
4. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
5. Correlation of c-erbB-2 amplification and risk of recurrence disease in node negative breast cancer
6. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
7. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer
8. erbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer
9. Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastases and poor long-term survival in breast cancer
10. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
11. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
12. HER2 overexpression decreases the benefit of adjuvant tamoxifen in early stage breast cancer without axillary node metastases
13. Prognostic importance of c-erbB-2 expression in breast cancer
14. Her-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
15. Independent prognostic factor in breast cancer patients
16. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
17. c-erbB-2 Expression and response to adjuvant therapy in women with node-positive early breast cancer
18. erb-B2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
19. Pathologic prognostic factors. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
20. Detection of amplified oncogenes by differential polymerase chain reaction
21. The NEU oncogene encodes an epidermal growth factor receptor-related protein
22. c-erbB-2 Expression in correlation to other biological parameters of breast cancer
23. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma
24. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
25. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy
26. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A southwest oncology group study
27. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-indepedent growth in human breast cancer cells
28. Expression of topoisomerase II alpha is associated with rapid cell proliferation, aneuploidy and c-erbB2 overexpression in breast cancer
29. Topoisomerase inhibitors and multiple drug resistance mechanism in human breast cancer